Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór złośliwy jelita grubego (rak gruczołowy)
- •Przerzuty w wątrobie, których nie można chirurgicznie usunąć
- •Wiek 18 lat lub więcej
- •Stan ogólny dobry, umożliwiający leczenie
- •Wcześniejsze leczenie co najmniej dwoma schematami chemioterapii
- •Przerzuty zajmują poniżej 50% objętości wątroby
- •Prawidłowe wyniki badań krwi i funkcji narządów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact:
Providence, United States
Trial contact
Brown University Oncology Research Group (BrUOG)
Alexander G Raufi, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.